Levetiracetam reduces myoclonus in corticobasal degeneration: report of two cases.
Levetiracetam (LEV) has been shown to suppress myoclonus of various origins. Corticobasal degeneration (CBD), a progressive neurodegenerative disorder with Parkinsonian syndrome, is frequently accompanied by myoclonus. We investigated the effect of LEV on myoclonus in two CBD patients. LEV remarkably decreased the myoclonic activity in both patients already at 1,500 mg/day dose. This is the first report on LEV alleviating myoclonus in CBD. Our data indicate that it might be worthwhile to assess this effect in an appropriately designed study.
Kovács
Tibor
T
Department of Neurology, Semmelweis University, 1083, Budapest, Balassa u. 6, Hungary. tibor@neur.sote.hu
Farsang
Marianna
M
Vitaszil
Edina
E
Barsi
Péter
P
Györke
Tamás
T
Szirmai
Imre
I
Kamondi
Anita
A
D000927:Anticonvulsants / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000077287:Levetiracetam; D008297:Male; D008875:Middle Aged; D009207:Myoclonus / Q000188:drug therapy* / Q000209:etiology; D019636:Neurodegenerative Diseases / Q000150:complications / Q000188:drug therapy*; D010889:Piracetam / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000927:Anticonvulsants; D000077287:Levetiracetam; D010889:Piracetam